左昔孟旦联合托伐普坦治疗急性失代偿性心力衰竭患者的疗效观察  

The Efficacy of Levosimendan Combined With Tolvaptan in the Treatment of Patients With Acute Decompensated Heart Failure

作　　者：王丽辉 姜晶 WANG Lihui;JIANG Jing(Department of Cardiology,Beijing Hospital of Integrated Traditional Chinese and Western Medicine,Beijing 100039,China;Department of Ultrasound,Beijing Hospital of Integrated Traditional Chinese and Western Medicine,Beijing 100039,China)

机构地区：[1]北京中西医结合医院心内科,北京100039 [2]北京中西医结合医院超声科,北京100039

出　　处：《中国卫生标准管理》2024年第11期114-117,共4页China Health Standard Management

摘　　要：目的探讨将左昔孟旦、托伐普坦2种药物联合应用于急性失代偿性心力衰竭疾病中的临床价值。方法选取北京中西医结合医院2021年6月-2023年8月接受治疗的56例急性失代偿性心力衰竭患者,并根据研究对象的治疗差异性进行分组对比干预。设接受常规治疗的为对照组,而接受左昔孟旦联合托伐普坦治疗为研究组,各28例。对比2组用药后的治疗疗效、血清相关指标、心功能指标以及不良反应。结果治疗后,研究组有效率(96.43%)高于对照组(78.57%)(χ^(2)=4.082,P=0.043)。治疗后,研究组的血清降钙素原、N末端脑利钠肽前体、白细胞介素-6以及超敏C-反应蛋白、左心室舒张末期内径、左心室收缩末期内径值均低于对照组,而左心室射血分数值高于对照组(P<0.05)。研究组的不良反应率为3.57%,低于对照组的28.57%(χ^(2)=4.766,P=0.029)。结论左西孟旦、托伐普坦联合应用于急性失代偿期心力衰竭中能明显改善血流动力学状态和心脏功能,从而促进临床症状缓解。而且,这2种药安全性均较高,值得临床进一步研究。Objective To explore the clinical value of levocimentan and tolvaptan in the treatment of acute decompensated heart failure.Methods A total of 56 patients with acute decompensated heart failure who received treatment in Beijing Hospital of Integrated Traditional Chinese and Western Medicine from June 2021 to August 2023 were selected,and divided into groups according to the treatment differences of the study subjects.The control group receiving conventional treatment was set up,while the study group receiving levoximandan combined with torvastan was set up,with 28 cases in each group.The therapeutic effect,serum related indexes,cardiac function indexes and adverse reactions were compared between the two groups.Results After treatment,the efficacy of the study group(96.43%)was higher than that of the control group(78.57%)(χ^(2)=4.082,P=0.043).After treatment,the values of serum procalcitonin,N-terminal brain natriuretic peptide precursor,interleukin-6 and hypersensitive C-reactive protein,left ventricular end-diastolic diameter and left ventricular end-systolic diameter in the study group were lower than those in the control group,but the values of left ventricular ejection fraction were higher than those in the control group(P<0.05).The adverse reaction rate of the study group was 3.57%lower than that of the control group(28.57%)(χ^(2)=4.766,P=0.029).Conclusion The combination of levosimendan and tolvaptan in acute decompensated heart failure can significantly improve the hemodynamic status and cardiac function,so as to promote the relief of clinical symptoms.Moreover,both of these drugs have high safety and further clinical research is warranted.

关 键 词：左昔孟旦 托伐普坦 急性失代偿性心力衰竭 疗效 血清降钙素原 N末端脑利钠肽前体 

分 类 号：R541[医药卫生—心血管疾病]